Preferred Label : BXQ-350 Nanovesicle Formulation;
NCIt synonyms : Saposin C-Dioleoylphosphatidylserine Complexes; SapC-DOPS Nanovesicles; Saposin C-Dioleoylphosphatidylserine Nanovesicles;
NCIt related terms : SAPOSIN C (NON-GLYCOSYLATED);
NCIt definition : A stable, nanovesicle formulation composed of a synthetic form of the human glycoprotein
saposin C (SapC) linked to the phospholipid dioleoylphosphatidylserine (DOPS), with
potential antineoplastic activity. Upon intravenous administration, the BXQ-350 nanovesicle
formulation selectively targets and preferentially accumulates in tumor vessels and
cells, due to the leaky nature of tumor vasculature and the presence of phosphatidylserine
(PS) lipids in tumor cell membranes. Upon binding to the phospholipids in the tumor
cell membrane, SapC fuses with the membrane and is internalized leading to its accumulation
within the internal membrane. SapC becomes active in the acidic tumor microenvironment
and as a lysosomal sphingolipid activator protein, activates lysosomal enzymes, such
as beta-glucosidase, acid sphingomyelinase, and beta-galactosylceramidase. This leads
to the degradation of glucosylceramide and sphingomyelin, and the conversion of galactosylceramide
to ceramide, respectively. This elevates intracellular ceramide levels, activates
caspases and induces ceramide-mediated apoptosis, which together lead to an inhibition
of tumor cell growth. SapC plays key roles in lipid transport and organization of
biological membranes and has strong lipid membrane binding activity.;
UNII : 2N62LTC861;
Molecule name : BXQ-350;
NCI Metathesaurus CUI : CL514261;
Origin ID : C131491;
UMLS CUI : C4329442;
Semantic type(s)
- concept_is_in_subset
